Comparing SAB Biotherapeutics (SABS) and The Competition

SAB Biotherapeutics (NASDAQ:SABS) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare SAB Biotherapeutics to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Insider & Institutional Ownership

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.5% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 15.8% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for SAB Biotherapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0	0	5	0	3.00
SAB Biotherapeutics Competitors	1999	5510	14177	309	2.58

SAB Biotherapeutics presently has a consensus price target of $11.40, indicating a potential upside of 507.35%. As a group, “Biological products, except diagnostic” companies have a potential upside of 132.58%. Given SAB Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than its competitors.

Earnings & Valuation

This table compares SAB Biotherapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
SAB Biotherapeutics	$2.24 million	-$42.19 million	-0.51
SAB Biotherapeutics Competitors	$583.57 million	-$70.96 million	3.99

SAB Biotherapeutics’ competitors have higher revenue, but lower earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares SAB Biotherapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%
SAB Biotherapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Risk and Volatility

SAB Biotherapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics’ competitors have a beta of -4.57, meaning that their average share price is 557% less volatile than the S&P 500.

Summary

SAB Biotherapeutics beats its competitors on 8 of the 13 factors compared.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.